Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Pleural Malignant Mesothelioma

Interventions: Drug: GC1008

First Posted Date: 2010-04-28

Last Posted Date: 2020-04-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 14

Registration Number: NCT01112293

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Nelfinavir

First Posted Date: 2010-04-22

Last Posted Date: 2021-07-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 7

Registration Number: NCT01108666

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Biological: CD40 agonist monoclonal antibody CP-870,893
Biological: tremelimumab
Other: laboratory biomarker analysis

First Posted Date: 2010-04-14

Last Posted Date: 2020-04-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 25

Registration Number: NCT01103635

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer

Interventions: Radiation: proton beam radiation therapy
Drug: cisplatin
Drug: etoposide
Procedure: therapeutic conventional surgery

First Posted Date: 2010-02-26

Last Posted Date: 2021-05-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 34

Registration Number: NCT01076231

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Radiation Therapy in Treating Patients With Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Proton Beam Radiation Therapy
Other: Quality-of-Life assessment
Other: Questionnaire Administration

First Posted Date: 2010-01-08

Last Posted Date: 2023-02-01

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 300

Registration Number: NCT01045226

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Phase 2

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Stage IV Verrucous Carcinoma of the Larynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Oropharynx

Interventions: Drug: lapatinib ditosylate
Drug: capecitabine

First Posted Date: 2010-01-07

Last Posted Date: 2020-03-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 44

Registration Number: NCT01044433

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma
Liver Cancer
Localized Unresectable Liver Cancer

Interventions: Drug: sorafenib tosylate
Drug: doxorubicin hydrochloride
Drug: cisplatin
Drug: mitomycin C
Procedure: transarterial chemoembolization
Procedure: hepatic artery embolization

First Posted Date: 2010-01-05

Last Posted Date: 2013-02-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT01042041

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Recurrent Melanoma
Stage III Malignant Testicular Germ Cell Tumor
Stage III Ovarian Germ Cell Tumor
Stage IV Rectal Cancer
Adenocarcinoma of the Colon
Adult Central Nervous System Germ Cell Tumor
Benign Teratoma
HER2-positive Breast Cancer
Ovarian Immature Teratoma

Interventions: Drug: PD-0332991

First Posted Date: 2009-12-23

Last Posted Date: 2021-03-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 304

Registration Number: NCT01037790

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma

Not Applicable

Withdrawn

Conditions: Adult Soft Tissue Sarcoma

Interventions: Radiation: Proton Beam Radiation Therapy

First Posted Date: 2009-12-17

Last Posted Date: 2021-06-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT01034566

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Phase 1

Completed

Conditions: Prostate Cancer
Stage II Prostate Cancer
Stage I Prostate Cancer
Stage III Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Procedure: radiation therapy treatment planning/simulation
Procedure: intensity-modulated radiation therapy
Procedure: image-guided radiation therapy
Procedure: magnetic resonance imaging
Procedure: computed tomography

First Posted Date: 2009-12-09

Last Posted Date: 2019-07-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT01028885

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Home Terms & Conditions Privacy Policy